Drugs & Targets Keytruda’s sBLA receives Priority Review from FDA for second-line treatment of relapsed or refractory classical Hodgkin lymphoma July 10, 2020Vol.46 No.28
Drugs & Targets Lynparza approved in EU for germline BRCA-mutated metastatic pancreatic cancer July 10, 2020Vol.46 No.28
Drugs & Targets Phesgo receives FDA approval in breast cancer indication for at home treatment July 02, 2020Vol.46 No.27
Drugs & Targets Keytruda receives FDA approval as first-line immunotherapy for MSI-H/dMMR MCC July 02, 2020Vol.46 No.27
Drugs & Targets Bavencio receives FDA approval for urothelial carcinoma maintenance treatment July 02, 2020Vol.46 No.27
Drugs & Targets Reblozyl approved by European Commission for transfusion-dependent anemia in adults with MDS or beta thalassemia July 02, 2020Vol.46 No.27
Drugs & Targets Guardant Health launches real-world clinical-genomic platform to accelerate precision oncology drug development July 02, 2020Vol.46 No.27
Drugs & TargetsFree FDA approves Keytruda for cutaneous squamous cell carcinoma June 26, 2020Vol.46 No.26
Drugs & TargetsFree Selinexor receives FDA approval for relapsed/refractory diffuse large B-cell lymphoma June 26, 2020Vol.46 No.26
